| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000022760 |
| Receipt No. | R000026221 |
| Official scientific title of the study | A randomized double-blind placebo-controlled trial for improving the intestinal environment in human |
| Date of disclosure of the study information | 2017/09/01 |
| Last modified on | 2018/11/15 (Ver. 6) |
| Basic information | ||
| Official scientific title of the study | A randomized double-blind placebo-controlled trial for improving the intestinal environment in human | |
| Title of the study (Brief title) | A trial for improving the intestinal environment in human | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To verify the improvement of intestinal environment due to ingestion of the test food. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Confirmatory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | 1. Enterobacterial flora (Bifidobacterium, Lactobacillales, Bacteroides, Prevotella, Clostridium cluster IV, Clostridium cluster IX, Clostridium cluster XI, Clostridium cluster XVIII, Clostridium subcluster XIVa, and others)
*1 Perform the test at 0 week and at 1 and 2 weeks after the ingestion |
| Key secondary outcomes | 1. The Japanese version of Constipation Assessment Scale MT version (CAS-MT)
*1 Perform the test at 0 week and at 1 and 2 weeks after the ingestion 2. Stool form scale *2 Perform the test at 0 week and at 1 and 2 weeks after the ingestion 3. Bowel movement diary *3 Recording about the defecation every day |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Duration: 2 weeks
Test material: "Onaka Kaichou Sengen" Dose: Take 3 sticks a day Administration: Once a day during a meal |
|
| Interventions/Control_2 | Duration: 2 weeks
Test material: Placebo Dose: Take 3 sticks a day Administration: Once a day during a meal |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Healthy Japanese adults
2. Persons who defecate two to five times per week |
|||
| Key exclusion criteria | 1. Subjects who have at least one previous medical history of malignant tumor, heart failure or myocardial infarction
2. Subjects who being treated for at least one of following diseases: cardiac arrhythmia, hepatic disorder, renal disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension or other chronic diseases 3. Subjects who currently take medicines (include herbal medicines) 4. Subjects who currently take Food for Specified Health Uses, Foods with Functional Claims, yogurt, and/or lactic fermenting beverage 5. Subjects who are allergic to medicines or foods related to the test food of this trial 6. Subjects who currently take supplements or fortified foods 7. Subjects who are pregnant, lactating, or planning to get pregnant during the trial period 8. Subjects who have enrolled into other clinical trials within the last 3 months before agreeing to participate in this trial 9. Subjects are judged as unsuitable for participating in this trial by physician for other reasons |
|||
| Target sample size | 40 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuo YAMAMOTO |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| kazu@orthomedico.jp | |
| Public contact | |
| Name of contact person | Naoko SUZUKI |
| Organization | ORTHOMEDICO, Inc. |
| Division name | R&D Department |
| Address | 2F Sumitomo Fudosan Korakuen Bldg., 1-4-1 Koishikawa, Bunkyo-ku, Tokyo. |
| TEL | 03-3818-0610 |
| Homepage URL | |
| nao@orthomedico.jp | |
| Sponsor | |
| Institute | ORTHOMEDICO, Inc. |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Aishitoto Co., Ltd |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | Seishin-kai Medical Association Inc, Takara Medical Clinic. |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 医療法人社団 盛心会 タカラクリニック
Seishin-kai Medical Association Inc, Takara Medical Clinic. |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | Hoshino T, Yamashita S, Suzuki N, Takara T. Effects of Food Containing Resistant Dextrin and Galactooligosaccharides on the Intestinal Environment in Healthy Japanese Adults. -A Randomized, Double-blind, Placebo-controlled, Parallel-group Trial-. Jpn Pharmacol Ther. 2018; 46(10): 1707-1722 |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000026221 |